Vaccine deal turnaround

Funding for non-biodefense medical research will be diverted to pay for anthrax vaccine

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

A deal reportedly proposed last week to resolve an ongoing dispute between the Bush Administration and Congress over funding to procure anthrax vaccine appears to have fallen through. A letter sent Wednesday (July 2) from the White House Office of Management and Budget (OMB) to a Senate subcommittee outlines a plan that would take money earmarked for other research supported by the National Institute of Allergy and Infectious Diseases (NIAID) to pay for the anthrax vaccine.

In a May letter, Senators Arlen Specter (R-Pa.) and Tom Harkin (D-Iowa) warned former OMB Director Mitch Daniels not to use any fiscal year 2003 (FY03) funds to procure the second-generation recombinant antigen (rPa) vaccine until Daniels and the senators discussed the matter. As chair and ranking member, respectively, of the Senate Appropriations subcommittee that oversees the National Institutes of Health, the senators were upset that OMB had ordered NIAID to scavenge $233 million ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • John Dudley Miller

    This person does not yet have a bio.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development